Juan Antonio Vega Ramiro

USPTO Granted Patents = 10 (Patent Applications = 6)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 56(Granted Patents)

Company Filing History:

8 out of 159

Janssen Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

patents

where one patent can have more than one assignee

Years Active: 2014-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10071095 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders (2018-09-11),

2. 9840507 - 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) (2017-12-12),

3. 9737533 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2017-08-22),

4. 9346811 - 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) (2016-05-24),

5. 9271967 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors (2016-03-01),

6. 9226930 - 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2016-01-05),

7. 9012448 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors (2015-04-21),

8. 8993591 - 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors (2015-03-31),

9. 8937060 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2015-01-20),

10. 8785486 - Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors (2014-07-22),

Title: The Innovative Journey of Juan Antonio Vega Ramiro

Introduction

Juan Antonio Vega Ramiro, an esteemed inventor based in Toledo, Spain, has made significant contributions to the field of pharmaceutical science. With a remarkable portfolio of 10 patents under his name, Vega Ramiro's work primarily focuses on developing novel therapeutic compounds for treating neurological and psychiatric disorders. His innovative approaches have garnered attention and respect within the scientific community.

Latest Patents

Among his latest inventions, Juan Antonio Vega Ramiro has developed the following notable patents:

1. **1,2,4-triazolo[4,3-A]pyridine Derivatives**: This invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives. These compounds act as positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2), proving beneficial for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.

2. **5,6-Dihydro-Imidazo[1,2-a]Pyrazin-8-ylamine Derivatives**: In another groundbreaking invention, Vega Ramiro has developed inhibitors of beta-secretase, which are instrumental in the prevention and treatment of several cognitive disorders, including Alzheimer’s disease, dementia, and other age-related conditions.

Career Highlights

Juan Antonio Vega Ramiro's career has been marked by his work with prominent pharmaceutical companies. His notable associations include Janssen Pharmaceuticals, Inc. and Addex Pharma. These experiences have shaped his expertise in drug discovery and development, allowing him to create innovative solutions for complex medical challenges.

Collaborations

Throughout his career, Vega Ramiro has collaborated with talented professionals, including Gary John Tresadern and Daniel Oehlrich. Their joint efforts have advanced the progress of innovative pharmaceutical therapies, further enhancing the impact of Juan Antonio's inventions.

Conclusion

Juan Antonio Vega Ramiro exemplifies the spirit of innovation in the pharmaceutical industry. His extensive portfolio of patents and collaboration with esteemed colleagues highlight his commitment to addressing critical neurological and psychiatric disorders. As his career progresses, the scientific community eagerly anticipates his future contributions, which hold the potential for significant advancements in therapeutic treatments.

This text is generated by artificial intelligence and may not be accurate.